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Type I interferon (IFN) has been approved as an anticancer agent to treat some malignancies.
However, IFNs have a short in vivo half-life, systemic toxicity, and poor biophysical properties,
which prevent it from being widely used for cancer therapy. This study aimed to construct
recombinant IFN-β-1a mutein immunocytokines that comprise a human epidermal growth
factor receptor 2 (HER2)-targeting antibody and IFN-β muteins with an additional
glycosylation, which can overcome the limitation of the cytokine itself. Hence, the
molecular design aims to 1) enhance productivity and biophysical properties by adding
secondary glycosylation in IFN-β, 2) increase the therapeutic index of IFN-β therapy by
preferential retention at the tumor by possessing high affinity for HER2-expressing cancer cells,
and 3) improve the pharmacokinetics and, thus, the convenience of IFN-β administration. The
yield of trastuzumab-IFN-βmutein was higher than that of trastuzumab-wild-type IFN-β in the
mammalian cell culture system. Trastuzumab-IFN-β mutein showed similar IFN activity and
HER2-targeting ability equivalent to that of IFN-β mutein and trastuzumab, respectively.
Trastuzumab-IFN-β mutein directly inhibited the growth of HER2-positive gastric cancer
cell lines and was more effective than trastuzumab or IFN-β mutein alone. Trastuzumab-
IFN-β mutein and IFN-β mutein displayed enhanced immune cell-mediated cytotoxicity.
Collectively, trastuzumab-IFN-β mutein may have indirect immune cell-mediated antitumor
effects and direct cell growth inhibitory effects. Tumor-targeting effect of trastuzumab-IFN-β
mutein was analyzed using in vivo fluorescence imaging. The accumulation of trastuzumab-
IFN-βmutein was observed in HER2-positive tumors rather than other tissues except the liver.
To evaluate the both direct tumor growth inhibition effect and indirect immune cell-mediated
antitumor effect, we tested the effect of trastuzumab-IFN-β mutein in HER2-positive cancer
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xenograft models using nude mice or humanized mice. Trastuzumab-IFN-β mutein could
significantly enhance tumor regression when compared with trastuzumab or IFN-β mutein. In
addition, an increase in tumor-infiltrating lymphocytes was observed in the trastuzumab-IFN-β
mutein-treated group, implying that the tumor-targeting IFN-β may have an enhanced
antitumor effect through increased immune response. Therefore, targeting IFN-β with an
anti-HER2 monoclonal antibody makes the immunocytokine more potent than either agent
alone. These novel findings suggest that trastuzumab-IFN-β mutein merits clinical evaluation
as a new candidate of anticancer therapeutics.
Keywords: HER2, trastuzumab, interferon-beta mutein, immunocytokine, tumor-targeting, immune cell-mediated
cytotoxicity
INTRODUCTION
During the last decade, the pleiotropic antitumor effects of type I
interferons (IFNs) have been studied, with specific reference to
their direct role on cancer cells and indirect action through the
immune effector cells and tumor vasculature (Borden, 2019).
Based on the antitumor efficacy, a recombinant human type I
IFN, IFN-α2, has been approved for the treatment of different
types of cancers (Borden et al., 2007). However, systemic
administration of IFNs has severe technical limitations that
must be overcome. This mainly includes the failure to achieve
optimal concentrations within the tumor bed after administration
of tolerable dose of IFNs. IFNs have short half-lives (Radwanski
et al., 1987; Salmon et al., 1996), and pharmacokinetic studies
have shown that only a tiny fraction of the injected dose
(approximately 0.01%) reaches the targeted tumor regions and
draining lymph nodes (Suzuki et al., 2003). Since the potential of
cytokine therapies are impaired due to dose-limiting systemic
toxicities, novel treatment methods should be developed to safely
deliver effective drug quantities at the tumor sites relative to the
whole body (Young et al., 2014).
Antibody-drug conjugates (ADCs) has been attempted to
induce organ-targeting and alleviate systemic side effects, and
several ADCs such as trastuzumab emtansine (T-DM1) have
been successfully approved (Hoffmann et al., 2018). When
conjugated with an antibody, higher doses of payload can be
tolerated (Poon et al., 2013). Immunocytokines share a similar
development concept, so it is predicted that they could
improve the therapeutic window of cytokines. In cases of
IFNs, various conjugates with monoclonal antibody (mAb)
targeted against tumor-associated proteins, such as EGFR,
HER2, CD20, CD38, and CD137, showed antiproliferative
effects in murine models of either hematological
malignancies or solid tumors (Huang et al., 2007; Rossi
et al., 2009; Dubrot et al., 2011; Trinh et al., 2013; Yang
et al., 2014; Vega et al., 2015; Pogue et al., 2016). Tumor
suppression was mediated by IFN α/β receptor on the cells
(Xuan et al., 2010) and/or through a more effective tumor
antigen presentation by DCs to CD8+ T cells (Yang et al.,
2014). In addition, therapeutic advantages of IFN-antibody
conjugates might be derived through immunomodulation and
angiogenesis blockade (Greiner et al., 1991; Ozzello et al., 1995;
Sivaraman et al., 2000; Li et al., 2017).
The uncertainty of IFN’s inter-species reactivity discourages
the development of human type I IFN derivatives for clinical
application. The limited cross-reactivity is probably due to low
cross-species identification (Harari et al., 2014). Cytokines
including type I IFNs, IL-2, IL-7, IL-15, and TNFα, attract
attention as anticancer agents (Conlon et al., 2019), and their
receptors have 50–80% homologies between humans andmice. In
particular, type I IFN receptors and IFN-β had the least homology
(less than 50%), and as a result, other cytokines had some cross-
reactivity, whereas IFN- β did not (Mosmann et al., 1987;
Seckinger et al., 1990; Eisenman et al., 2002; Barata et al.,
2006). Human to mouse cross-reactivity is a very important
factor, especially in conducting in vivo experiments. Because it
is very difficult to evaluate the full efficacy and toxicity of human
IFN-β substrates to host cells in murine models, most preclinical
studies used mouse IFN surrogates to analyze the in vivo effect,
and revealed the underlying mechanisms. Nevertheless, for
clinically relevant studies, human form of IFN substrates
should be tested.
In our previous studies, we developed a glycoengineered
variant of recombinant human IFN-β-1a, IFN-β-R27T, which
has two N-glycosylation sites at the 80th (original site) and an
additional one at the 25th amino acid residue due to a mutation of
Thr to Arg at position 27 of IFN-β (Song et al., 2014). IFN-
β-R27T exhibited superior stability, solubility, productivity, and
pharmacokinetic properties compared to wild-type IFN-β-1a
(Lee et al., 2019; Song et al., 2020). Herein, we constructed
fusion proteins consisting of an anti-HER2 antibody
(trastuzumab) with IFN-β mutein and investigated its
antitumor effect on a HER2-positive model.
MATERIALS AND METHODS
Antibody and Antibody-Cytokine Fusion
Proteins
The trastuzumab- and trastuzumab-IFN-β mutein-expressing
gene constructs were generated by gene synthesis
(Cosmogenetech, Seoul, Korea), and the synthesized heavy and
light chain DNAs were inserted into the pCHO 1.0 expression
vector (Life Technologies, Gaithersburg, MD, United States) at
the AvrII-Bstz17I and EcoRV-PacI sites of the polylinker region,
respectively (Supplementary Table S1). CHO-S cells (Life
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Technologies, Gaithersburg, MD, United States) were transfected
with the expression vectors, and stable clones were selected with
100–10,000 nM of methotrexate (Sigma, NY, United States) and
10–50 μg/ml of puromycin (Life Technologies, Gaithersburg,
MD, United States). Culture media from CHO-S cells stably
expressing trastuzumab and trastuzumab-IFN-β muteins were
collected and loaded onto a MabSelect SuReTM rProtein A
agarose-bead resin (GE Healthcare, WI, United States), and
the proteins were eluted using 0.1 M sodium citrate buffer (pH
3.0). The purified antibody and antibody-cytokine fusion proteins
were quantified using the Cedex Bio Analyzer (Roche,
Indianapolis, IN, United States) and analyzed using sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) under reducing and non-reducing conditions.
Cell Lines and Cell Culture
Human gastric carcinoma cell lines (NCI-N87, YCC-19, YCC-38,
KATOIII, Hs746T, and MKN74), normal gastric epithelial cell
line (HFE145), and normal primary human umbilical vein
endothelial cell line (HUVEC) were used in this study. NCI-
N87 and HUVEC cell lines were purchased from the American
Type Culture Collection (ATCC; Manassas, VA, United States).
KATOIII, Hs746T, and MKN74 cell lines were purchased from
Korean Cell Line Bank (KCLB; Seoul, Korea). YCC-19 and YCC-
38 cell lines were established and provided by Sun Young Rha
(Yensei University, Seoul, Korea) (Kim et al., 2018). HFE145 cell
line was provided by Hassan Ashktorab (Howard University,
MD, United States) (Marlink et al., 2003). All cell lines were
cultured with RPMI 1640 Medium (Hyclone, Logan, UT,
United States) supplemented with 10% fetal bovine serum
(FBS) (Hyclone, Logan, UT, United States), 100 units/ml
penicillin, and 100 μg/ml streptomycin (Hyclone, Logan, UT,
United States). HUVECs were maintained in VascuLife EnGS
(containing endothelial cell growth supplement; Lifeline Cell
Technology, Frederick, MD, United States). All cultured cells
were incubated at 37°C in a cell culture incubator with 5% CO2.
Three-Dimensional (3D) Structure, Circular
Dichroism, and Size Analysis
The 3D structure of trastuzumab-IFN-β was predicted using the
Protein Data Bank (PDB) files of trastuzumab and IFN- β-1a. To
determine the secondary structures of trastuzumab-IFN-β-R27T
(trastuzumab-R27T), circular dichroism spectra were obtained
using a Chirascan-plus circular dichroism spectrometer (Applied
Photophysics Ltd., Surrey, United Kingdom). The spectra were
measured between the wavelengths of 190 and 260 nm in the
presence of samples diluted in phosphate-buffered saline (PBS).
The secondary structure of the trastuzumab-R27T was analyzed
using CDNN secondary structure analysis software (Applied
Photophysics Ltd., Surrey, United Kingdom). The size of
trastuzumab-R27T was measured using dynamic light scattering.
Flow Cytometry Analysis
To analyze the HER2 binding of trastuzumab and trastuzumab-
R27T, NCI-N87 and HUVEC cells were detached with enzyme-
free, PBS-based cell dissociation buffer (Gibco, Gaithersburg,
MD, United States). The cells were incubated with 1 μg/ml of
human immunoglobulin G1 (IgG) (Jackson Immunoresearch
Laboratories, West Grove, PA, United States), trastuzumab or
trastuzumab-R27T in PBS containing 1% FBS for 1 h at 4°C. The
cells were then washed twice and incubated with fluorescein
isothiocyanate (FITC)-conjugated anti-human secondary
antibody (diluted 1:100; Santa Cruz Biotechnology, Danvers,
MA, United States). Stained cells were analyzed using a BD
FACSCalibur system equipped with Cell Quest Pro software
(BD Biosciences, San Jose, CA, United States).
Immunofluorescence Analysis
NCI-N87 and HUVECs were seeded in four-well culture slides
(SPL, Seoul, Korea), grown to 80% confluence and treated with
trastuzumab or trastuzumab-R27T for 1 h. The cell culture slides were
washed with PBS, and cells were fixed using 4% paraformaldehyde for
15min. The cells were incubated with FITC-conjugated anti-human
secondary antibody (Santa Cruz, Danvers, MA, United States) for 1 h
and stained with 4,6-diamidino-2-phonylindole dihydrochloride. The
slides were removed from chamber and mounted for digital
micrographs, which were taken using the LSM 700 ZEISS laser
scanning confocal microscope (Carl Zeiss, Jena, Germany). The
data were processed using LSM co-localization software (Carl
Zeiss, Jena, Germany).
IFN Luciferase Assay
IFN reporter gene assays were performed using iLite® Type I IFN
assay ready cells (Euro Diagnostica, Malmo, Sweden) and a
luciferase assay kit (Promega, Madison, WI, United States).
Briefly, iLite® Type I IFN assay ready cells were seeded in a
96-well plate and treated with IFN-β-R27T, trastuzumab, or
trastuzumab-R27T. After 18 h, type I IFN promoter activity
was quantified by measuring the firefly luciferase luminescence
using a microplate reader (TECAN, Männedorf, Switzerland).
Cell Viability Assay
To perform the cell viability assay, NCI-N87, YCC-19, YCC-38,
KATOIII, Hs746T, MKN74, or HFE145 cells were seeded in 96-
well plates, cultured overnight, and treated with various
concentrations of IFN-β-R27T, trastuzumab, or trastuzumab-
R27T for 72 h. Cell viability was assessed by Water-Soluble
Tetrazolium (WST) colorimetric assay (Ez-Cytox; DogenBio,
Seoul, Korea). Absorbance was measured at 450 nm using a
microplate reader (TECAN, Männedorf, Switzerland). Percent
growth was calculated according to the NCI-60 DTP Human
Tumor Cell Line Screen protocol as follows:
% Growth  (treated viability – viability at time 0)/(vehicle
control viability – viability at time 0) × 100.
Growth inhibition of 50% (GI50) and the maximum inhibitory
effect at the highest drug concentration (Emax) values were estimated
using GraphPad Prism 7.0 software (San Diego, CA, United States).
Immune Cell-Mediated Cytotoxicity Assay
Human peripheral blood mononuclear cells (PBMCs) were
purchased from Stem Express (Placerville, CA, United States).
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CD14+ monocytes, CD8+ T cells, CD4+ T cells, or natural killer
(NK) cells were purified from human PBMCs using magnetic-
activated cell sorting (Miltenyi Biotech GmbH, Bergisch Gladbach,
Germany) according to the manufacturer’s instructions. To
perform the immune cell-mediated cytotoxic assay, the human
gastric cancer cells were seeded at 1 × 104 cells per well in 96-well
plates. The next day, tumor cells were co-cultured with each
effector cell population at 0.5:1, 1:1, 2:1, 4:1, 8:1, and 16:1
effector-to-target cell (E:T) ratios in the absence or presence of
control IgG, trastuzumab, IFN-β-R27T, or trastuzumab-R27T for
72 h. After incubation, cell viability was assessed by WST
colorimetric assay (DoGenBio, Seoul, Korea). Absorbance at
wavelength 450 nm was read using a microplate reader
(TECAN, Männedorf, Switzerland), and data were recorded and
normalized by respective blank using target and effector cell
culture. In the wash-out study, NCI-N87 or Hs746T cells were
pre-treated with control IgG, trastuzumab, IFN-β-R27T, or
trastuzumab before co-culture with PBMC. After 6 h, the cells
were washed with PBS twice and then co-cultured with PBMCs.
Antibody-Dependent Cell-Mediated
Cytotoxicity Assay
The ADCC assay was performed in four human gastric cancer cell
lines (NCI-N87, YCC-19, KATOIII, and Hs746T) and two normal
cell lines (HFE145 and HUVEC). Target cells were seeded in 96-well
plates at a density of 2 × 104 cells/well and incubated overnight. The
NK-92MI-CD16a cells, which stably express CD16a, were previously
established and used as effector cells (Yang et al., 2020). The target
cells were incubated with control IgG, IFN-β-R27T, or trastuzumab-
R27T at a final concentration of up to 10,000 nM and 8 × 104 effector
cells in a CO2 incubator for 4 h at 37°C (E:T ratio  4:1). Target cell
lysis was measured by detecting the release of lactate dehydrogenase
using CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega,
Madison, WI, United States) according to the manufacturer’s
instructions. The absorbance of the plates was analyzed using the
Spark TM 10M microplate reader (TECAN, Männedorf,
Switzerland) at 490 nm. For data analysis, the percentage of
specific ADCC was calculated as follows:
% Cytotoxicity  (Experimental – Effector Spontaneous –
Target Spontaneous)/(Target Maximum – Target
Spontaneous) × 100.
The dose–response curve and EC50 values were estimated
using GraphPad Prism 7 (GraphPad Software, San Diego, CA,
United States).
Tumor-Targeting Analysis in a
HER-2-Positive Tumor Xenograft Mouse
Model
Control IgG-IFN-β-C17S/R27T (IgG-C17S/R27T) and
trastuzumab-IFN-β-C17S/R27T (trastuzumab-C17S/R27T) were
labeled with fluorescent dye CF750 (Biotium Inc., Hayward,
CA, United States) through amide linkage in basic condition in
accordance with the manufacturer’s instructions. Since IFN-
β-R27T is susceptible to pH stress (Song et al., 2020), C17S was
additionally addressed to reduce nonspecific events that occur
during labeling. C17S mutation increases stability without
affecting IFN-β activity (Runkel et al., 1998), allowing it to
generate more stable and high yield products while maintaining
the properties of IFN-β-R27T (Supplementary Figure S1).
To generate xenografts, 5 × 106 NCI-N87 or Hs746T cells were
resuspended in 100 µL PBS and injected subcutaneously into the
right flank of six-week-old BALB/c-nude mice (Orient Bio,
Seongnam, Gyeonggi, Korea). Tumor-bearing mice were treated
intravenously with CF750-labeled antibody-cytokine fusion
proteins (100 µg/100 µL in PBS). After 1, 6, and 24 h, the mice
were anesthetized with Terrell TM isoflurane (Piramal Critical
Care Inc., Bethlehem, PA, United States) and placed in Ami HTX
(Spectral Instruments Imaging, Tucson, AZ, United States) to
visualize CF750-labeled antibody-cytokine fusion proteins. The
fluorescence was detected using an excitation filter (710 nm)
and an emission filter (790 nm). At the final time point, the
mice were sacrificed, and the liver, kidney, spleen, lung,
intestine, and tumor were excised. The organs from each mouse
were placed, and the intensity of fluorescence was analyzed using
Aura imaging software (Spectral Instruments Imaging, Arizona,
United States). The average fluorescence intensity was calculated by
creating a region of interest for each organ. The animal experiment
was approved by the Institutional Animal Care andUse Committee
(IACUC) of Seoul National University (SNU-200307-1).
Human Gastric Cancer Xenograft Nude
Mice Model
The antitumor efficacy of trastuzumab-IFN-βmutein in vivo was
tested in NCI-N87 xenograft models. The animal experiment was
approved by the Institutional Animal Care and Use Committee
(IACUC) of Seoul National University (SNU-190528-2-1). Five-
week-old male/female BALB/c-nude mice (Orient Bio, Seongnam,
Gyeonggi, South Korea) were subcutaneously inoculated at the
dorsal right side with 5 × 106 cells. NCI-N87-bearing mice were
intraperitoneally treated with trastuzumab, IFN-β-R27T, or
trastuzumab-R27T (10mg/kg) thrice a week for 3 weeks. Tumor
size was measured using a Vernier caliper in two dimensions, and
the tumor volumewas calculated using the following formula: tumor
volume (mm3)  (short diameter)2 × (long diameter) × 0.5.
Humanized Gastric Cancer Xenograft in
Humanized Mice
To establish humanized mice, mononuclear cells were separated
from human umbilical cord blood obtained after normal full-
term deliveries. Informed consent was obtained from donor
according to institution guidelines, and these experiments were
approved by Seoul Metropolitan Government Seoul National
University Boramae Medical Center (IRB No. 16-2014-80) and
Seoul National University Institutional Review Board (IRB No.
E1409/002-001). This study is conducted in accordance with the
World Medical Associtation’s Declaration of Helsinki. CD34+
hematopoietic stem cells (HSCs) were isolated using a direct
CD34+ MicroBead kit (Miltenyi Biotec, CA, United States). Five-
week-old female NSG mice (Jackson Laboratory, PA
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United States) were preconditioned with 30 mg/kg of busulfan
(MedChemExpress, Monmouth Junction, NJ, United States).
Approximately, over 90% purified 1 × 105 of freshly isolated
CD34+ HSCs were injected intravenously into mice 24 h after
preconditioning. The engraftment levels of human CD45+ cells
and human immune cell populations were determined in the
peripheral blood using a color flow cytometry panel. Mice that
had over 25% human CD45+ cells in the peripheral blood were
considered humanized. Humanized mice were randomized into
every treatment group for all experiments. All humanized mice
were confirmed for humanization before tumor xenograft.
To generate subcutaneous xenograft tumor models, 1 × 106
NCI-N87 or YCC-19 cells were implanted in the right flank of
humanized mice. Tumor-bearing humanized mice were
randomized into the treatment and non-treatment groups.
Three humanized mice per group, from one donor, were used
for xenograft experiments. Tumor-bearing humanized mice were
treated with trastuzumab, IFN-β-R27T, or trastuzumab-R27T
intraperitoneally thrice a week for 3 weeks. The control group
received intraperitoneal injections of the saline vehicle. Mice were
monitored routinely, and tumor size was measured with calipers
at the endpoint, and volumes (in mm3) were calculated using the
formula (length × width2)/2. For immune analysis, mice from
each treatment groups were sacrificed, and tumor tissues were
harvested for IHC. Harvested tissues were fixed with 4%
paraformaldehyde for 24 h and paraffin-embedded for
immunostaining with the indicated antibodies. Human
forkhead box P3 (FOXP3; clone D9M8I), CD68 (clone
D4B9C), and programmed death-ligand 1 (PD-L1; clone
E1L3N) antibodies were purchased from Cell Signaling
Technology (United States), and human CD8 antibody was
purchased from Invitrogen (United States). Histology slides
were analyzed with a photomicroscope (Olympus, Miami, FL,
United States) at a final magnification of 200×. Six images from
each group were captured using NIS-Element BR software
(Nikon, Shizuoka, Japan).
Statistical Analysis
Data were presented as means ± standard deviation (SD) and
were statistically analyzed using one or two-way analysis of
variance with appropriate post hoc analysis for multiple
groups or student’s unpaired two-tailed t-tests. A p value less
that 0.05 was considered statistically significant. All statistical
analyses were performed using GraphPad Prism 7.0 software (San
Diego, CA, United States).
RESULTS
Generation of Trastuzumab-IFN-β Mutein
Fusion Protein
We generated an anti-HER2 antibody conjugated IFN-β-R27T
fusion protein (trastuzumab-R27T), in which a 15-mer flexible
peptide linker (GGGGSGGGGSGGGSG) was used to link IFN-
β-R27T to the C-terminus of each heavy chain of trastuzumab
(Figure 1A). Trastuzumab-R27T was expressed in Chinese
hamster ovary (CHO) cells and secreted in the culture
medium. The proteins were purified and separated by SDS-
PAGE under reducing and non-reducing conditions. The band
representing the heavy chain of the fusion protein was observed
between the 70 and 100 kDa marker bands, which confirmed that
IFN-β-R27T was successfully fused to the heavy chain
(Supplementary Figure S2A). The fusion protein showed a
higher molecular weight than the trastuzumab band under
non-reducing conditions (Supplementary Figure S2B). Next,
we compared the expression levels of trastuzumab-wild-type
IFN-β and trastuzumab-R27T fusion proteins in CHO-S cells.
Expression analysis revealed that trastuzumab-R27T showed
higher expression levels than trastuzumab-wild-type IFN-β
(Supplementary Figure S2C). In addition, IgG quantification
analysis revealed that the expression level of trastuzumab-R27T
was six-fold higher than that of trastuzumab-wild-type IFN-β
(Supplementary Figure S2D). The results are consistent with our
previous research on IFN-β-R27T that showed six-fold higher
productivity compared to wild-type IFN-β (Song et al., 2014). To
summarize, these results suggest that trastuzumab-R27T is
appropriately conjugated and produced more stably and
efficiently.
The 3D structure of trastuzumab-R27T was visualized using
the PDB files for trastuzumab and IFN-β-1a (Figure 1B). The size
of trastuzumab-R27T was approximately 16.8 nm, which
corresponds to the combined size of IFN-β-R27T (3.7 nm) and
trastuzumab (11.4 nm) (Figure 1C). Moreover, the secondary
structural analysis revealed that the trastuzumab-R27T tends to
form α-helices that are 9.85% higher than that of trastuzumab,
mainly due to the conjugation of IFN-β (Figure 1D).
Bioactivity of the Trastuzumab-IFN-β
Mutein Fusion Protein
To investigate whether the bioactivity of trastuzumab-R27T was
maintained, the effects of trastuzumab-R27T on anti-HER2 and
IFN activity were evaluated. First, we used the U937 iLite® type I
IFN assay ready cell system to confirm the bioactivity of
trastuzumab-R27T. This cell line expresses firefly luciferase
under the control of IFN-responsive promoter. The result
showed that trastuzumab-R27T increased luciferase activity
and had similar luminescence as that of IFN-β-R27T
(Figure 2A). Since U937 iLite® ready cells do not express
HER2 (Figure 2A, insert), the IFN activation in the cells
induced by trastuzumab-R27T was independent of HER2
expression. The IFN signaling is mediated through the binding
of type I IFN receptors and the subsequent phosphorylation of
signal transducers and activators of transcription (STATs)
(Darnell et al., 1994). Trastuzumab-R27T induced robust
STAT1 phosphorylation in both NCI-N87 and Hs746T gastric
cancer cells harboring high and low HER2 expression,
respectively (Figure 2B). These results indicate that the
cytokine attached to the C-terminal heavy chain of
trastuzumab with a polypeptide linker is sterically distant from
the antigen-binding region, and is flexible enough to allow
engagement with its receptor. Second, to determine the HER2-
targeting function of trastuzumab-R27T, HUVEC (HER2-
negative) or NCI-N87 cells (HER2-positive) were stained with
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trastuzumab or the fusion protein. Flow cytometry analysis
revealed that trastuzumab and trastuzumab-R27T showed
similar binding abilities in both cell lines, indicating that the
fusion protein retained the ability to bind to HER2 (Figure 2C).
NCI-N87 cell membrane was positively stained by both
trastuzumab and fusion protein, whereas HUVECs did not
show any other binding (Figure 2D). Overall, the IFN-β
mutein-fused trastuzumab possessed both IFN activity and
HER2-targeting ability equivalent to that of IFN-β mutein and
trastuzumab, respectively.
In vitro Antitumor Effect of the
Trastuzumab-IFN-β Mutein Fusion Protein
Type I IFNs have a direct antiproliferative or cytotoxic effect on
primary malignant cells from patients with multiple myeloma
FIGURE 1 | Generation of trastuzumab-IFN-β mutein fusion protein. (A) Schematic representation of trastuzumab-IFN-β mutein and its constituents. The fusion
protein was generated by fusing IFN-βmutein to the C-terminus of the trastuzumab heavy chain via 15-mer flexible peptide linker (GGGGSGGGGSGGGSG). (B)Amodel
structure of trastuzumab-IFN-β. 3D structure of trastuzumab-IFN-βwas predicted in silico. (C) The size of trastuzumab-IFN-βwasmeasured by dynamic light scattering.
(D) Structural analysis of trastuzumab-R27T. The CD spectra of IFN-β-R27T, trastuzumab, and trastuzumab-R27T were measured. The secondary structural
contents were analyzed using the CDNN program.
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and melanoma (Schiller et al., 1986; Grandér et al., 1993) and a
few tumor cell lines, such as WM9, Daudi, and OVCAR3
(Leaman et al., 2003; Kim et al., 2017). We compared the
antitumor activity of trastuzumab, IFN-β-R27T, and
trastuzumab-R27T using an in vitro proliferation assay with
HER2-positive (NCI-N87, YCC-19, YCC-38, and SNU216;
Figure 3A and Supplementary Figure S3A) and HER2-
negative (KATOIII, Hs746T, MKN74, and MKN45;
Figure 3B and Supplementary Figure S3B) gastric cancer
cell lines and a normal gastric epithelial cell line (HFE145;
FIGURE 2 | Anti-HER2 and IFN-β bioactivity of trastuzumab-IFN-β mutein. (A) Type I IFN function of trastuzumab-R27T. U937 cells stably expressing an ISG
promoter-firefly gene were treated with or without the indicated concentration of trastuzumab, IFN-β-R27T, or trastuzumab-R27T. After 18 h, the firefly luciferase
activities were determined. (B) STAT1 phosphorylation of trastuzumab-R27T. NCI-N87 or Hs746T cells were treated with or without trastuzumab, IFN-β-R27T, or
trastuzumab-R27T for the indicated times. The cell lysates were analyzed by western blotting with the indicated antibodies. (C) HER2 binding assay. HUVECs and
NCI-N87 cells were stained with trastuzumab or trastuzumab-R27T, and fluorescence-positive cells were measured by flow cytometry. (D) Analysis of HER2-targeting
function by confocal microscopy. HUVECs and NCI-N87 cells were incubated with trastuzumab, IFN-β-R27T, or trastuzumab-R27T for 1 h, and cellular fluorescence
was observed by confocal microscopy. Each bar is the mean of three replicates, and error bars represent standard deviation (SD), **p < 0.01 vs. vehicle control.
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Figure 3C). The GI50 and Emax values of trastuzumab, IFN-
β-R27T, and trastuzumab-R27T are summarized in Table 1.
Trastuzumab-R27T strongly inhibited (Emax  88.9–100%)
HER2-positive cancer cells with high potency (GI50 
0.006–0.062 nM); however, trastuzumab slightly inhibited
(Emax  14.1–50.4%) HER2-positive cancer cells and had no
inhibitory effect on HER2-negative gastric cancer cell lines and
the normal gastric epithelial cell line. IFN-β-R27T showed a
similar or slightly weak inhibitory effect on cancer cells
compared to trastuzumab-R27T, indicating that the
antitumor effect of trastuzumab-R27T is mainly due to IFN-
β than that of trastuzumab. Interestingly, both IFN-β mutein-
containing drugs (trastuzumab-R27T and IFN-β-R27T) had
strong antitumor effect on all four HER2-positive cell lines,
whereas differential antitumor reactivity was shown in HER2-
negative cell lines. Furthermore, the antitumor activity of IFN-
β was not correlated with type I IFN receptor expression
(Figure 3D).
Immune Cell-Mediated Anticancer Effect of
the Trastuzumab-IFN-β Mutein Fusion
Protein
Type I IFNs have been proven to be involved in immune system
regulation (Hervas-Stubbs et al., 2011). To test whether
trastuzumab-IFN-β mutein can activate the antitumor
responses of immune cells, we measured PBMC-mediated
cytotoxicity in HER2-positive (NCI-N87) or HER2-negative
(Hs746T and KATOIII) cells. PBMCs from healthy donors
were co-cultured with NCI-N87, Hs746T or KATOIII cells at
different E:T ratios ranging from 0.5:1 to 16:1 in the presence of
0.1 nM of human IgG, trastuzumab, IFN-β-R27T, or trastuzumab-
FIGURE 3 | In vitro direct antitumor effect of trastuzumab-IFN-βmutein on different gastric cancer cell lines. (A) HER2-positive (NCI-N87, YCC-19, and YCC-38),
(B) HER2-negative (KATOIII, Hs746T, and MKN74) cancer cell lines, or (C) normal gastric epithelial cells (HFE145) were treated with trastuzumab, IFN-β-R27T, or
trastuzumab-R27T for 72 h. Cell growth (%) was determined using theWST assay. Each point is the mean of three replicates, and error bars represent SD. (D)HER2 and
Type I IFN receptor 1 expression in gastric cancer cell lines and normal gastric epithelial cell line.
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R27T. Co-culture with PBMCs exhibited the antitumor function in
a certain E:T ratio (Figure 4A; Supplementary Figure S4).
Notably, treatment with IFN-β-R27T or trastuzumab-R27T
enhanced PBMC-mediated cytotoxicity in all three cell lines,
whereas IgG or trastuzumab had no additional effect.
To examine the type of immune cells that contributed to the
antitumor effects, the cytotoxic effects of CD4+ T cells, CD8+
T cells, NK cells, or CD14+ monocytes were tested in the NCI-
N87 co-culture system. Each cell type was isolated using
magnetic bead separation from healthy PBMCs. As shown in
Figure 4B, all types of immune cells played a role in restraining
NCI-N87 cells. Treatment with IFN-β-R27T or trastuzumab-
R27T enhanced the antitumor effect in the presence of each
immune cell type. In particular, co-culture with CD8+ T cells or
NK cells showed the most synergistic cytotoxic effect on NCI-
N87 cells in combination with IFN-β-R27T or trastuzumab-
R27T. NK cells form a small subset among lymphocytes;
however, they are considered the most important cells
capable of inducing ADCC in trastuzumab-mediated
therapies (Beano et al., 2008). Because activating NK cells
rapidly downregulate the expression of Fc gamma receptor
III-A (CD16a) (Peruzzi et al., 2013; Romee et al., 2013), co-
culture with NK cells from PBMCs did not show sufficient
ADCC effect by trastuzumab. To validate the ADCC effect by
NK cells, we measured ADCC activity using NK-92MI-CD16
TABLE 1 | The aGI50 and
bEmax values of trastuzumab, IFN-β-R27T, and
trastuzumab-R27T.
Cell lines Trastuzumab IFN-β-R27T Trastuzumab-R27T
GI50 (nM) Emax (%) GI50 (nM) Emax (%) GI50 (nM) Emax (%)
NCI-N87 4.38 50.4 0.098 76.1 0.042 88.9
YCC19 >100 34.7 0.034 104.8 0.006 100
YCC38 >100 14.1 0.071 74.0 0.062 89.5
KATOIII >100 6.5 0.128 64.4 0.018 56.6
Hs746T >100 0 >100 19.3 >100 21.5
MKN74 >100 0 >100 0 >100 0
HFE145 >100 6.5 >100 0 >100 0.3
aGI50: The concentration of drug needed to inhibit cell growth by 50%.
bEmax: The growth inhibition percent at the highest drug concentration.
FIGURE 4 | Synergistic effect of trastuzumab-IFN-βmutein on immune cell-mediated cytotoxicity in gastric cancer cell lines. (A) PBMCs co-cultured with gastric cancer
cells were treated with 0.1 nM of control IgG, trastuzumab, IFN-β-R27T, or trastuzumab-R27T. At 72 h post treatment, cell viability was measured using the WST assay.
(B) Specific effects of CD8, CD4, NK, and CD14+ cells co-cultured with NCI-N87 cells alone or combined with each drug. NCI-N87 cells were co-cultured with sorted CD8+
T cells, CD4+ T cells, NKcells, andCD14+monocytes at indicated E:T ratio, alone or in combinationwith each drug. Data represent themean±SD (n 3), *p < 0.05, **p <
0.01 vs. control IgG at each E: T ratio, assessed by two-way ANOVA with Turkey’s multiple comparison test. (C) ADCC activity of trastuzumab-R27T in a HER2-dependent
manner in various gastric cancer cell lines. Cancer cells were incubated with effector cells at an E:T ratio of 8:1 and various concentration of each drug for 6 h. Cytotoxicity
(%) was determined by measuring released lactate dehydrogenase (LDH) and normalizing to a maximum LDH release in the presence of Triton X-100 (100% cell lysis).
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cell line, which is a genetically engineered cell line with sufficient
activity (Yang et al., 2020). Treatment of trastuzumab-R27T
showed a similar ADCC effect as that of trastuzumab in HER2-
positive cancer cell lines, suggesting that trastuzumab-R27T is
capable of causing significant ADCC (Figure 4C). These results
suggested that the immune response mediated by trastuzumab-
IFN-β mutein increased the cytotoxic activity of all types of
immune cells, especially the primary effector cells, CD8+ T and
NK cells, which exerted significant antitumor effects.
Tumor-Targeting of Trastuzumab-IFN-β
Mutein
As shown in Figures 3, 4, IFN-β exhibited both direct cell killing
and immune cell-mediated cytotoxicity even in HER2-negative
cancer. However, the cytokines that are not targeted to tumors are
actually difficult to maintain this effect in an in vivo environment.
The primary goal of developing immunocytokines is to expand
the therapeutic index of IFN-β by preferential retention at the
tumor sites by possessing high affinity for antigen-expressing
cancer cells. To reveal the importance of the tumor-targeting
effect of IFN-β on immune cell-mediated tumor cytotoxicity, we
performed a wash-out study in NCI-N87 and Hs746T cells. In the
wash-out condition, cancer cells were treated with each drug for
6 h, washed with the completed media, and then co-cultured with
PBMCs (Figure 5A). Because treated drugs were intactly
remained in the media under non-wash condition, the PBMC-
mediated cytotoxic effect of IFN-β-R27T or trastuzumab-R27T
was observed in both cell lines (Figures 5B,C). In contrast, drug
washing led to the loss of these effects with IFN-β-R27T, while
with trastuzumab-R27T they were retained in NCI-N87 cells
(Figure 5B right). Although this result was slightly reduced due to
the removal of free form of trastuzumab-R27T, tumor-bound
trastuzumab-R27T was sufficient to produce cytotoxicity.
However, the PBMC-mediated cytotoxic effects were not
shown in Hs746T cells under wash-out condition (Figure 5C
right). These results highlight the importance of providing IFN-β
with a tumor-targeting property.
To demonstrate the in vivo tumor-targeting properties of
trastuzumab-IFN-β mutein depend on whether HER2 is
expressed or not, fluorescence imaging assay was conducted in
xenograft mice bearing tumors with HER2 positive (NCI-N87) or
negative (Hs746T). IgG-C17S/R27T, a fusion protein consisting
of human IgG with IFN-β mutein as a non-targeting agent, and
trastuzumab-C17S/R27T were conjugated with the fluorescence
dye (CF750). Further, 100 µg of CF750-labeled control IgG-C17S/
R27T or trastuzumab-C17S/R27T was intravenously injected in
BALB/c nude mice bearing NCI-N87 or Hs746T to evaluate the
tumor-targeting properties of these agents. On a qualitative basis,
in vivo fluorescence imaging indicated that the fusion proteins
were locally concentrated in the tumor and liver for 24 h after
administration (Figures 6A,C). In addition, quantitative ex vivo
measurements of the dissected organs of NCI-N87 tumor-bearing
mice confirmed that trastuzumab-C17S/R27T targeted the
HER2-positive tumor with more than four-fold high local
concentration compared to control IgG-C17S/R27T
(Figure 6B). In contrast to NCI-N87, there was no difference
in tissue distribution, including in the tumor (Figure 6D).
Collectively, the results demonstrated that trastuzumab-IFN-
β-mutein was guided to the tumor in an HER2 dependent
manner.
In vivo Effect of Trastuzumab-IFN-β Mutein
The in vivo therapeutic performance of trastuzumab-IFN-β
mutein was tested in BALB/c nude mice bearing NCI-N87
tumors. After the tumor volume reached the average volume of
150 mm3, the mice were treated with trastuzumab, IFN-
β-R27T, or trastuzumab-R27T thrice a week for three weeks.
Compared to vehicle control, trastuzumab, IFN-β-R27T, or
trastuzumab-R27T inhibited the tumor growth effectively
without a change in weight (Figures 7A,B). Although
antitumor effect of trastuzumab-R27T is mostly similar to
IFN-β-R27T in vitro, it was significantly higher than that of
IFN-β-R27T in vivo. Because biophysical properties such as
half-life and biodistribution are considerable factors for in vivo
effect, the cytokine had no strong in vivo effects than the
in vitro effects. However, trastuzumab-IFN-β mutein, which
FIGURE 5 | In vitro tumor-targeting effect of trastuzumab-IFN-β mutein
on immune cell-mediated tumor cytotoxicity. (A) Overview of the wash-out
study procedure. In the wash-out condition, NCI-N87 cells were pre-treated
with each drug before co-culture with PBMCs. After 6 h, cells were
washed with PBS twice and then co-cultured with PBMCs at 1:1E:T ratio for
72 h (B,C) Comparison of anticancer effect of tumor-targeting of IFN-β-R27T
in accordance with anti-HER2 antibody fusion in NCI-N87 (B) or Hs746T (C).
Data represent the mean ± SD (n  3), **p < 0.01; N.S., not significant.
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improved the biophysical properties of the cytokine and is
endowed with tumor-targeting, exhibited superior efficacy over
IFN-β-R27T.
The tumor regression effect of trastuzumab-R27T in the
xenograft model only reflected the direct cancer cell growth
inhibitory effects and did not include the immune cell-
FIGURE 6 | Tumor targeting effect of trastuzumab-IFN-βmutein in xenograft mice bearing HER2-positive or HER2-negative tumor. (A,C) NCI-N87 (A) or
Hs746T (C) cells were transplanted subcutaneously into BALB/c-nude mice. CF750–control IgG-C17S/R27T or CF750–trastuzumab-C17S/R27T was
intravenously injected at a dose of 100 μg/mouse, and the fluorescence intensity was monitored at 1, 6, and 24 h (B,D) Tissues from NCI-N87 (B) or Hs746T
(D) xenograft mice were isolated at 24 h post-injection, and the ex vivo fluorescence images were observed. The ex vivo fluorescence images from each
tissue were quantified as the average radiant efficiency. Data represent the mean ± SD (n  3), **p < 0.01 vs. control IgG-C17S/R27T.
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mediated antitumor effects. Because human IFN-β rarely
responds to mouse cells (Harari et al., 2014), an in vivo model
with a human immune system is required to reveal the immune
responses. Hence, we developed CD34+ human hematopoietic
stem cell-derived humanized mice, which recapitulated the
human immune system (De La Rochere et al., 2018). Further,
two humanized gastric cancer models were established using
NCI-N87 and YCC-19. In both models, tumor size was
significantly reduced in all treatment groups compared to
vehicle control. Particularly, trastuzumab-R27T had greater
efficiency than trastuzumab or IFN-β-R27T alone in both
NCI-N87 and YCC-19 humanized xenograft tumor models
(Figures 8A,B).
Immune cell infiltration to tumor tissue is necessary for the
prognosis of patients and the response to immunotherapies
(Fridman et al., 2017). So, we investigated the prevalence of
tumor-infiltrating lymphocytes in NCI-N87 bearing humanized
mice. The immunohistochemistry (IHC) analysis revealed that
increased numbers of CD8+ T cells (CD8+) were observed in
small tumors responding to trastuzumab-R27T therapy relative
to controls (Figure 8C). The percentages of CD8+ T cells in the
tumors of trastuzumab-R27T-treated mice were significantly
higher than that of control tumors. In addition, type I IFNs
negatively regulated the proliferation of regulatory T cells,
which directly suppressed the activity of cytotoxic T cells
(Pace et al., 2010; Sisirak et al., 2012). The number of
regulator T cells (FOXP3+) was significantly decreased in the
trastuzumab-R27T-treated group. All examined tumors
exhibited very low numbers of monocyte (CD14+) cells and
B cells (CD20+) in association with high macrophage (CD68+)
numbers regardless of the treatment (data not shown and
Figure 8C). PD-L1 was detected in tumor cells and stromal
immune cells. The expressions of PD-L1 in tumor cells tended
to be slightly increased by trastuzumab-R27T, which might be
due to type I IFN-induced PD-L1 expression (Garcia-Diaz et al.,
2017). Taken together, these data suggest that tumor repression
by trastuzumab-IFN-βmutein relies on both direct and indirect
immune cell-mediated cytotoxic activities.
DISCUSSION
This is the first study to describe the production of a novel
immunocytokine comprising a human IFN-β, which selectively
targets the HER2-positive tumor tissues, achieving a high local
concentration of the cytokine at the site. In this study, we used
IFN-β-R27T, a biobetter of IFN-β, to generate immunocytokine
instead of wild-type IFN-β. We had developed the
glycoengineered IFN- β-R27T mutant; the additional
glycosylation makes it more physicochemically stable (Song
et al., 2014). Several studies have revealed that undesirable
physicohemical properties of IFN-β primarily cause the
various types of its instability, such as aggregation, oxidation,
deamidation, and disulfide changes. Therefore, IFN-β
instability during the culture, purification, and storage of the
commercial product has been investigated to decrease
instability, especially aggregation, improve productivity and
maintain functional activity (Rodriguez et al., 2005; Han
et al., 2009; Rodriguez et al., 2010). IFN-β-R27T is less
susceptible to biophysical instability, such as aggregation,
than Wild-type IFN- β. Consequently, the productivity of
IFN-β-R27T was approximately 3–6 times higher than that
of wild-type IFN-β (Song et al., 2014). It is likely that this
was a consequence of lesser aggregation resulting from the
additional glycosylation, since it is well known that low
productivity of IFN-β is caused by molecular aggregation.
For immunocytokines, the stability of the proteins tends to
be determined primarily by the cytokine rather than the
antibody (Sommavilla et al., 2010; Schneider et al., 2019).
This is because antibodies are very stable, whereas cytokines
are relatively unstable, resulting in product-related impurities.
The productivity of trastuzumab-R27T was higher than that of
trastuzumab-wild-type IFN-β. This is probably because of the
same reason why IFN-β-R27T showed up to 6-fold higher
productivity than wild-type IFN-β.
The fusion protein potently inhibited human HER2-high
gastric and breast cancers (Supplementary Figure S5) in direct
manner. In contrast, HER2-low cancers showed differential
FIGURE 7 | The in vivo direct effect of trastuzumab-IFN-βmutein in NCI-
N87 xenograft model. (A) Tumor volume gain curve of mice treated with
vehicle, trastuzumab, IFN-β-R27T, or trastuzumab-R27T (n  4 per group).
Dot line indicated the date of drug treatment. Tumor volume analysis was
performed by two-way ANOVA. Data represent mean ± SD, *p < 0.05; **p <
0.01. (B) The percent of body weight gain curve.
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response to IFN-β, even though STAT1 phosphorylation by IFN
was observed (Figure 2B). Interestingly, the direct killing effect of
trastuzumab-R27T is primarily dependent on IFN-β rather than
trastuzumab in almost all cancer cell lines. However, its cytotoxic
sensitivity to cytokines seems to be correlated with HER2
expression. Our results are in line with a previous clinical
correlation study showed that IFN activity was associated with
a low risk in patients with HER2-positive breast cancer (Callari
et al., 2014) In addition, IFN could act as a regulatory factor
against HER2-positive cancers (Stagg et al., 2011; Castiello et al.,
2018). All these evidences indicate that the differences in the level
of HER2 expression would be associated with distinct biological
properties of cancer cells. To date, there has been no report on the
effect of HER2 on the responsiveness to type I IFN. Therefore, the
underlying mechanism of why higher IFN-induced cytolytic
activity is observed in HER2-positive cancers needs to be
studied in more depth in future research. The higher sensitivity
of neoplastic cells with high HER2 expression to IFN may have
clinical implications as it suggests the benefits of anti-HER2
conjugated IFN-β in patients with high-risk HER2-positive
cancer.
The in vitro antitumor effect of trastuzumab-R27T is mostly
dependent on IFN-β-R27T. However, the in vivo effect of
trastuzumab-R27T was significantly greater than that of IFN-
β-R27T (Figure 7). Unlike the in vitro situation, biophysical
properties, such as half-life and biodistribution, are considerable
factors for the effect of the drug in vivo. Despite the strong effect
of IFN-β, no strong in vivo effects were observed resembling those
in vitro. However, the immunocytokine, which improves the
short half-life of cytokine and is endowed with tumor-
targeting effects, retained its strong antitumor effect in vivo
and in vitro. In general, the half-life of cytokine is short,
ranging from several minutes to several hours. In the case of
IFN-β, serum concentrations following intravenous
administration decline rapidly, and the terminal half-life
ranges from 1 to 2 h in humans (Wills, 1990). Therefore,
FIGURE 8 | The in vivo effect of trastuzumab-IFN-βmutein in humanized gastric cancer xenograft models. (A,B) Tumor weight of humanizedmice bearing NCI-N87
(A) or YCC-19 (B) treated with vehicle, trastuzumab, IFN-β-R27T, or trastuzumab-R27T (n  3). Data represent mean ± SD, **p < 0.01 vs. vehicle. (C)
Immunohistochemistry analysis of tumor-infiltrating immune cells after treatment. 10 μm sections of tumors were stained for CD8 (cytotoxic T cell), FOXP3 (regulatory
T cell), CD68 (tumor-associated macrophage), and PD-L1 (immune check point). Magnification, ×100. Data represent mean ± SD, *p < 0.05, **p < 0.01 vs. vehicle.
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most drugs are lost before they reach an optimal concentration
in the target organs and have only a slight effect. Here, we fused
trastuzumab to IFN-β mutein, which has a half-life of 15 h
(unpublished data). Though its half-life is shorter than that of
the antibody (terminal half-life of trastuzumab: 12–16 days)
(Spilker et al., 2017), it causes a dramatic increase in half-life
when compared to cytokine (terminal half-life of IFN-β-R27T:
88 min) (Song et al., 2014). Therefore, our immunocytokine is
not merely the simple sum of a cytokine and an antibody, and it
could be valuable as novel entity that has different biophysical
properties than those of a cytokine or an antibody alone.
It is controversial whether the direct or indirect effect of IFNs
is the main anticancer mechanism. In several studies, type I
IFNs have direct inhibitory effects on tumor cells of different
origin, hence, they curb proliferation and drive senescence and
apoptosis. The immunocytokine, anti-CD20-IFN-α clearly
showed that type I IFNs could have direct cytotoxic effects in
lymphoma, which is very sensitive to type I IFN receptor-
mediated tumor killing (Rossi et al., 2009; Xuan et al., 2010;
Trinh et al., 2013). On the contrary, Yang at al. demonstrated
that antibody-fused mouse IFN-β regulates tumor growth
primarily by host (mouse) immune responses rather than
direct killing (Yang et al., 2014). They provided evidence that
the antibody fused mouse IFN-β enhanced cytotoxic T
lymphocytes activation creating a positive feedback loop to
kill more cells.
Given that the NCI-N87 cell line is IFN-sensitive, the in vivo
direct tumor killing effect of trastuzumab-R27T in the xenograft
model was consistent with the in vitro effect. Similarly, in our NCI-
N87 and YCC-19 xenograft model using humanized mice, the
direct antitumor effect of trastuzumab-R27T would also be
effective. Furthermore, it was found that the number of tumor-
infiltrating humanCD8+ T cells increased in the trastuzumab-R27T-
treated group in the humanized mice model. FOXP3 stained cells,
presumed to be regulatory T cells were significantly decreased by a
third compared to vehicle control. Rios-Doria et al. characterized
several xenograft models using humanized mice and revealed that
the antitumor response of the models to immunotherapy was
positively associated with the induced levels of CD4 and
CD8 tumor-infiltrating lymphocytes (Rios-Doria et al., 2020).
Moreover, CD8 T cells were essential for the antitumor immune
response of the murine IFN-β-immunocytokine (Yang et al., 2014).
Based on these studies, our results showing the infiltration of CD8
T cells in humanized mice model provided a meaningful evidence
for the immunological effects of human IFN-β immunocytokine.
Collectively, previous reports and our results complement each other
and cover two different modes of action for IFN-mediated tumor
regression.
There are several limitations in the present study. Due to
technical difficulties, we used tumor cell lines and did not freshly
isolate autologous tumors to assess the cytotoxic capabilities of
immune cells. Therefore, we mainly evaluated the antitumor
activity of immune cells, except for the analysis of autologous
tumor cells. Moreover, although we introduced humanized mice
to verify the role of immune cells in antitumor effect, the direct
anti-tumor effects were also mixed in the mice models, making it
difficult to evaluate only intact indirect effects. In fact, the most
important consideration of immunocytokine studies is the
possibility of reducing cytokine toxicity through antigenic
targeting. Unfortunately, it would be limited to evaluate the
full efficacy and toxicity of human IFN-β substrates to host
cells in murine models because human IFN-β rarely works in
mouse cells (Harari et al., 2014). Therefore, the development of
new models capable of evaluating intact human IFN-β is
required, which may accelerate the translational research of
human IFN-β.
In summary, the data presented in this study provide a
rationale for the clinical investigation of fully human analogs
of trastuzumab-IFN-β, which feature human IFN-β as the
therapeutic payload. Targeting IFN-β with an anti-HER2 mAb
makes the immunocytokine more potent than either agent alone.
Our findings suggest that trastuzumab-IFN-β mutein merits
clinical evaluation as a new candidate for anticancer therapeutics.
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